Thermo Fisher Scientific Aktie
| 525,51USD | 9,03USD | 1,75% |
WKN: 857209 / ISIN: US8835561023
Aktionärsstruktur
| Inhaber | in % |
|---|---|
| Freefloat | 99,87 |
| The Vanguard Group, Inc. | 8,62 |
| Vanguard Group, Inc. (Subfiler) | 8,20 |
| State Street Corp. | 4,27 |
| Vanguard Total Stock Market ETF | 3,15 |
| T Rowe Price Associates, Inc. (13F Subfiler) | 2,72 |
| Vanguard 500 Index Fund | 2,65 |
| Capital Research & Management Co. (World Investors) | 2,44 |
| BlackRock Fund Advisors | 2,29 |
| BlackRock Institutional Trust Co. NA | 2,19 |
| Capital Research & Management Co. (Global Investors) | 2,14 |
| Geode Capital Management LLC | 2,00 |
| Fidelity Management & Research Co. LLC | 1,54 |
| Norges Bank (13F) | 1,46 |
| Government Pension Fund - Global (The) | 1,43 |
*Die Summe der Anteile kann 100% überschreiten, da bestimmte Anteilseigner zum Freefloat dazu gerechnet wurden.
Personal
| 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Personal am Ende des Jahres | 75 000 | 80 000 | 130 000 | 130 000 | 122 000 |
| Umsatz pro Mitarbeiter in Mio. EUR | 0,34 | 0,40 | 0,30 | 0,35 | 0,35 |
Bilanz (in Mio. USD) - Aktiva
| 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Summe Umlaufvermögen | 11 893 | 21 957 | 20 113 | 25 229 | 24 589 |
| Summe Anlagevermögen | 46 488 | 47 095 | 75 010 | 71 925 | 74 137 |
| Summe Aktiva | 58 381 | 69 052 | 95 123 | 97 154 | 98 726 |
Bilanz (in Mio. USD) - Passiva
| 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Summe Fremdkapital | 28 706 | 34 545 | 54 146 | 53 006 | 51 884 |
| Summe Eigenkapital | 29 675 | 34 507 | 40 977 | 44 148 | 46 842 |
| Summe Passiva | 58 381 | 69 052 | 95 123 | 97 154 | 98 726 |
Adresse
| 168 Third Avenue, 02451 Waltham | |
| Telefon | +1 (781) 622-1000 |
| Fax | +1 (781) 622-1207 |
| Internet | http://www.thermofisher.com |
Management
|
Aditya Joshi
Chief Strategy Officer & Vice President |
|
Alan B. Sachs
Chief Medical Officer |
|
Anthony Hugh Smith
Treasurer, Vice President-Tax & Treasury |
|
C. Martin Harris
Independent Director |
|
Chetan Khanna
Director-Human Resources |
|
Cory Stevenson
President-Bioproduction Division |
|
Daniel P. Shine
Senior VP, President-Analytical Instruments |
|
Daniella Cramp
Senior VP & President-BioProduction Group |
|
Debora L. Spar
Independent Director |
|
Dion J. Weisler
Independent Director |
|
Frederick M. Lowery
President-Laboratory Products & Bioproduction |
|
Garret Hampton
President-Clinical Sequencing & Oncology |
|
Gianluca Pettiti
Executive Vice President |
|
James C. Mullen
Independent Director |
|
Jennifer M. Johnson
Independent Director |
|
John Brian Sabo
VP & General Counsel-Customer Channels Group |
|
Joseph Holmes
Chief Accounting Officer & Vice President |
|
Julia L. Chen
Secretary & Vice President |
|
Karen E. Nelson
Chief Scientific Officer |
|
Kathryn Miles
Vice President-Strategic Accounts |
|
Kimberlee S. Caple
Vice President & GM-Genetic Science Business |
|
Lisa P. Britt
Chief Human Resources Officer & Senior VP |
|
Marc N. Casper
Chairman, President & Chief Executive Officer |
|
Michael A. Boxer
Senior Vice President & General Counsel |
|
Michael J. Dubose
President-Fisher Healthcare Division |
|
Michel Lagarde
Chief Operating Officer & Executive Vice President |
|
Mike Shafer
Senior VP & President-Pharma Services Group |
|
Nelson J. Chai
Independent Director |
|
Paul G. Parker
Senior VP-Strategy & Corporate Development |
|
R. Alexandra Keith
Independent Director |
|
Rafael Tejada
Vice President-Investor Relations |
|
Ruby R. Chandy
Independent Director |
|
Ryan Snyder
Chief Information Officer & Senior Vice President |
|
Scott M. Sperling
Lead Independent Director |
|
Sebastian Pacios
Senior Vice President-Clinical Research |
|
Stephen Williamson
Chief Financial Officer & Senior Vice President |
|
Tyler E. Jacks
Director |
ETF-Sparplan
Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.
